NZOZ Regionalna Poradnia Diabetologiczna
- Address
- lock Available on a paid plan
Nutritional and Metabolic Diseases and Cardiovascular Diseases
At NZOZ Regionalna Poradnia Diabetologiczna in Wroclaw, clinical research focuses on type 2 diabetes mellitus and related cardiovascular disease, with studies aimed at improving blood sugar control and reducing heart-related risk.
- Testing whether adding new treatment combinations can improve glycemic control in people with poorly managed type 2 diabetes
- Comparing once-weekly and daily diabetes therapies to assess how well they support long-term blood glucose management
- Evaluating whether newer approaches may help lower the risk of major cardiovascular events in people with diabetes
The site’s trial portfolio reflects a strong interest in both metabolic care and heart health, with research designed to refine treatment effectiveness for patients living with type 2 diabetes mellitus.
Diabetes Treatment Optimization
This research area centers on improving therapy for type 2 diabetes when standard treatment is not enough, including studies that compare combination regimens and newer glucose-lowering medicines.
- Assessing the benefit of adding an extra diabetes medicine to existing therapy for better blood sugar control
- Studying whether weekly treatment options can match or improve the effectiveness of more frequent insulin-based care
- Exploring ways to support patients whose glycemic control remains inadequate despite ongoing treatment
These trials are intended to help identify more effective and practical treatment strategies for people with persistent type 2 diabetes mellitus.
Cardiometabolic Risk Research
Another key focus at this health care site is the connection between diabetes and cardiovascular disease, with studies examining whether newer therapies can improve protection against serious heart and blood vessel complications.
- Evaluating treatments designed to reduce the chance of major adverse cardiovascular events
- Comparing diabetes medicines for their ability to support both glucose control and heart health
- Studying patients with type 2 diabetes mellitus who also have elevated cardiovascular risk
Overall, the research aims to better understand how diabetes therapies may influence long-term cardiometabolic outcomes in routine clinical care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NZOZ Regionalna Poradnia Diabetologiczna
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5 | Novo Nordisk A/S | Phase III | Not Recruiting | — | Dec 2025 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Empagliflozin | 1 | Unknown | 2024-08-20 | 2024-08-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.